Despite current standards of care aimed at achieving targets for low-density lipoprotein
(LDL) cholesterol, blood pressure and glycaemia, dyslipidaemic patients remain at high …

Atorvastatin is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor. In dosages of 10 to 80 mg/day, atorvastatin reduces levels of total cholesterol, low …

Background—Familial combined hyperlipidemia (FCHL) and familial hypertriglyceridemia
(FHTG) are 2 of the most common familial forms of hyperlipidemia. There is a paucity of …

It has long been recognized that elevated triglyceride levels are associated with increased
risk for coronary heart disease (CHD). However, it has not been determined whether …

Combined hyperlipidemia (CHL) is characterized by a concomitant elevation of plasma
levels of triglyceride-rich, very low density lipoproteins (VLDLs) and cholesterol-rich, low …

Peroxisome proliferator–activated receptors (PPARs) form a family of nuclear hormone
receptors involved in energy hemostasis and lipid metabolism (1, 2) and include three …

Background Statins (3-hydroxy-3-methylglutaryl–coenzyme A [HMG-CoA] reductase
inhibitors) have been used for a decade to lower low-density lipoprotein (LDL) cholesterol …

This review provides an overview of the recent data evaluating triglyceride and low-density
lipoprotein (LDL) size, two highly interrelated, genetically influenced, risk factors for …

Therapeutic success of statins has distinctly established inhibition of de novo hepatic
cholesterol synthesis as an effective approach to lower plasma LDL-cholesterol, the major …

Dyslipidaemia is frequently present in obesity, metabolic syndrome (MetS) and type 2
diabetes mellitus (T2DM). The predominant features of dyslipidaemia in these disorders …